Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 2;11(1):7-19.
doi: 10.1586/17446651.2016.1113129. Epub 2015 Nov 18.

Insulin Degludec/Liraglutide (IDegLira) for the Treatment of Type 2 Diabetes

Affiliations
Free PMC article

Insulin Degludec/Liraglutide (IDegLira) for the Treatment of Type 2 Diabetes

Stephen Cl Gough et al. Expert Rev Endocrinol Metab. .
Free PMC article

Abstract

The progressive nature of type 2 diabetes necessitates that treatment is intensified as the disease advances. Several studies have shown that basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) can be used in combination to successfully improve glycemic control and this combination is increasingly being considered as an alternative to intensification with prandial insulin. Insulin degludec/liraglutide (IDegLira) is the first fixed-ratio combination of a basal insulin and a GLP-1RA in a single formulation. Here we consider the benefits and potential limitations of such a combination, focusing on the unique modes of action of insulin degludec and the once-daily GLP-1RA liraglutide. IDegLira offers an efficacious combination therapy (mean end-of-trial HbA1c was 6.4-6.9% across the five completed Phase 3 trials), which was well-tolerated in clinical trials. The complementary modes of action resulted in a low rate of hypoglycemia and no weight gain in insulin-treated patients. As a once-daily injection with effects on both fasting and post prandial hyperglycemia, IDegLira has the potential to help many patients reach glycemic target (60-81% of patients achieved HbA1c <7% in clinical trials).

Keywords: IDegLira; glucagon-like peptide-1 receptor agonist; insulin; type 2 diabetes.

Figures

Figure 1.
Figure 1.
Amino acid structure of native human GLP-1 and liraglutide [16].
Figure 2.
Figure 2.
Structure (A) and mechanism of protraction (B) of insulin degludec [34].
Figure 3.
Figure 3.
The IDegLira clinical trial program: DUAL.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Garber AJ, Abrahamson MJ, Barzilay JI. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–336. - PubMed
    1. Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2015;38:140–149. - PubMed
    1. Khunti K, Damci T, Meneghini L. Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab. 2012;14:654–661. - PubMed
    1. Valensi P, Benroubi M, Borzi V. The IMPROVE study–a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract. 2008;62:1809–1819. - PubMed
    1. Khunti K, Wolden ML, Thorsted BL. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417. - PMC - PubMed

LinkOut - more resources

Feedback